RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX icon
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$294K 0.02%
2,087
-1,124
-35% -$153K
2015 Q2
2 quarters
DBVT icon
52
DBV Technologies S.A. American Depositary Shares
DBVT
$561M
$290K 0.02%
799
-52,483
-99% -$18.3M
2015 Q3
1 quarter
ADVM icon
53
DELISTED
Adverum Biotechnologies
ADVM
$231K 0.02%
2,424
-72,418
-97% -$6.36M
2014 Q3
5 quarters
AXDX icon
54
DELISTED
Accelerate Diagnostics
AXDX
$215K 0.02%
+1,000
New +$183K
2015 Q4
0 quarters
CSLT
55
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$44K οΉ€0.01%
10,229
-724,168
-99% -$3.11M
2014 Q1
7 quarters
AUPH icon
56
Aurinia Pharmaceuticals
AUPH
$2.21B
$41K οΉ€0.01%
+16,610
New +$45.1K
2015 Q4
0 quarters
BMRN icon
57
BioMarin Pharmaceuticals
BMRN
$10.7B
– –
-368,775
Closed -$38.8M –
CERS icon
58
Cerus
CERS
$449M
– –
-1,603,427
Closed -$7.28M –
CLDX icon
59
Celldex Therapeutics
CLDX
$2.18B
– –
-130,268
Closed -$20.6M –
DVAX icon
60
DELISTED
Dynavax Technologies
DVAX
– –
-724,348
Closed -$17.8M –
JAZZ icon
61
Jazz Pharmaceuticals
JAZZ
$13.7B
– –
-1,769
Closed -$235K –
NGNE icon
62
Neurogene
NGNE
$426M
– –
-25,715
Closed -$7.24M –
PPH icon
63
VanEck Pharmaceutical ETF
PPH
$1.05B
– –
-6,500
Closed -$409K –
RGNX icon
64
Regenxbio
RGNX
$451M
– –
-277,000
Closed -$6.1M –
TNET icon
65
TriNet
TNET
$3.04B
– –
-639,186
Closed -$10.7M –
CMRX icon
66
DELISTED
Chimerix, Inc.
CMRX
– –
-1,067,978
Closed -$40.8M –
RAD
67
DELISTED
Rite Aid Corporation
RAD
– –
-403,570
Closed -$49M –
INFI
68
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-590,100
Closed -$4.99M –
CERN
69
DELISTED
Cerner Corp
CERN
– –
-3,563
Closed -$214K –
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-11,456
Closed -$628K –
NXTM
71
DELISTED
NxStage Medical Inc.
NXTM
– –
-11,800
Closed -$186K –
ZSPH
72
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-514,107
Closed -$33.8M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.